Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[G-CSF in oncology].

Frédéric Viret1, Anthony Gonçalves, Carole Tarpin

  • 1Département d'oncologie médicale, Institut Paoli-Calmettes, 232, boulevard Sainte-Marguerite, 13273 Marseille Cedex 09.

Bulletin Du Cancer
|June 17, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026
Same author

Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences.

Cancer communications (London, England)·2026
Same author

Prognostic value of lymphopenia in early breast cancer: learnings from the prospective CANTO cohort.

Breast cancer research : BCR·2026
Same author

Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women.

Breast (Edinburgh, Scotland)·2026
Same author

BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer.

Breast (Edinburgh, Scotland)·2026
Same author

Innovative Research Organization to Facilitate Clinical Trials Implementation in the Era of Molecular Oncology: The Spiderweb Model of the Oncodistinct Network.

JCO precision oncology·2026

Colony-stimulating factors (CSFs) effectively prevent febrile neutropenia (FN), a common chemotherapy side effect. These recombinant DNA-derived growth factors are crucial for managing infections and optimizing cancer treatment outcomes.

Area of Science:

  • Oncology
  • Hematology
  • Biotechnology

Background:

  • Neutropenia and febrile neutropenia (FN) are frequent, dose-limiting toxicities in cancer chemotherapy.
  • FN increases the risk of life-threatening infections and can lead to chemotherapy dose delays, potentially compromising treatment efficacy.

Purpose of the Study:

  • To review the clinical applications of colony-stimulating factors (CSFs) in oncology.
  • To highlight the role of CSFs in managing chemotherapy-induced neutropenia and its complications.

Main Methods:

  • Review of data supporting clinical applications of CSFs in oncology.
  • Discussion of recombinant DNA technology in hematopoiesis regulation.

Main Results:

  • Colony-stimulating factors (CSFs), including G-CSF and GM-CSF, are integral to preventing FN.

Related Experiment Videos

  • CSFs have established uses in FN prevention, treatment, peripheral stem cell mobilization, and post-transplant support.

    • Conclusions:

    • CSFs are vital in modern oncology for mitigating the risks associated with chemotherapy-induced neutropenia.
    • The clinical utility of CSFs in cancer care is well-supported by extensive data.